Effect and the safety of the selective COX-2 inhibitor parecoxib after pancreaticoduodenectomy under the direction of ERAS program

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032535

Enrollment

Unknown

Registered

2020-05-01

Start date

2017-10-09

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreaticoduodenectomy

Interventions

Parecoxib group:routine use of Parecoxib (40 mg iv Q12h) after PD

opioid group:temporary dose of opioid (pethidine or morphine) as wish after PD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 140 consecutive patients who receive a pancreaticoduodenectomy (PD or PPPD) for treatment of periampullary tumors in Peking University First Hospital will be recruited. 1. Aged from 18 to 75 yeas; 2. Understanding and cooperating the implementation of ERAS after surgery. 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have severe coexisting cardiopulmonary disease; 2. Long term postoperative tracheal intubation ventilation (>=3d); 3. Severe abnormality of liver or kidney function, including serum total bilirubin>170umol/L; 4. Any other reasons that cannot implement ERAS programmes after surgery; 5. Allergic to NSAIDs or COX-2 inhibitors.

Design outcomes

Primary

Measure	Time frame
pain score;the usage of opioid drug (frequency and accumulated dose);	—

Secondary

Measure	Time frame
the safety of long-term (5 days) use of Parecoxib on pain control for patients after PD procedure;anti-inflammatory effect of Parecoxib on postoperative patients;	—

Countries

China

Contacts

Public ContactXiaodong Tian

Peking University First Hospital

tianxiaodong@pkufh.cn+86 13911636280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026